Pharma and Healthcare Insight provides pharma market intelligence, trend analysis, forecasts and company profiles for the pharma industry on a country-by-country basis across North and South America, Central, Eastern and Western Europe, Asia, the Middle East and Africa. It gives access to the latest independent analysis of market data for the global pharma industry as well as a searchable archive of past articles and data.
» To access our 
RSS feed of headlines copy this link to your RSS reader
Industry / Brazil
Brazil's generic drug market grew by 24% in real terms during 2009, according to primary research firm IMS Health marking yet another year of rapid market share gains for the industry. The result was within 1.4% of BMI projections, which stood at 22.6%. In our view a similar market dynamic will prevail going forward. From 2009-2014 BMI forecasts that generic drug sales will increase...
2010-02-05Industry / United States
Pfizer's disappointing 2009 financial results are mainly due to declining sales of its mega-blockbuster Lipitor (atorvastatin) and poor returns in emerging markets. Although revenue...
2010-02-04Industry / Switzerland
Multinational drugmaker Novartis is to pay a US$185mn fine in order to settle criminal allegations relating to off-label promotion of the epilepsy drug Trileptal (oxcarbazepine),...
2010-01-28Industry / Hong Kong
Health expenditure in Hong Kong is expected to increase from HKD80.22bn (US$10.34bn) in 2009 to HKD83.19bn (US$10.69bn) in 2010 - a rise of 3.7% in local currency terms and 3.4% in US dollar terms. BMI notes that this forecast is above the 2004-2009 compound annual growth rate (CAGR) of 3.1%, mainly due to far-reaching market reforms implemented in early 2008. Through to 2014,...
2010-02-04Industry / Vietnam
A common feature of emerging markets is a preference for foreign pharmaceuticals over domestically-produced equivalents. Imported medicines are perceived as being of higher quality...
2010-02-02Industry / China
China's over-the-counter (OTC) medicine market is expected to increase from CNY86.4bn (US$12.63bn) in 2009 to CNY93.76bn (US$13.95bn) in 2010. Due to the strengthening yuan, this...
2010-02-01Industry / Russia
Russia's pharmaceutical manufacturing industry was hit hard during 2009, with production amounting to only 91.7% of 2008 levels, according to data released by the Ministry of Industry and Trade of the Russian Federation (Minpromtorg). These figures reflect difficulties associated with raw materials becoming more expensive due to ruble devaluation, general financial difficulties...
2010-02-05Companies / Slovenia
Slovenian generic drugmaker Krka plans to continue its strong organic growth strategy during 2010, while also eyeing potential takeover opportunities. Chief Executive Jože Colarič...
2010-02-04Industry / Bulgaria
Private health insurance funds look set to gain access to public resources for supplementary medical care, under amendments to Bulgaria's Law on Health Insurance. Long-awaited reforms...
2010-02-02Industry / Egypt
In BMI's recent analysis of the Gulf Co-operation Council (GCC) pharmaceutical market, we highlighted Saudi Arabia and the UAE as the biggest medicine spenders - reaching values of US$3.8bn and US$2.7bn by 2014, respectively. In BMI's Middle East and North Africa (MENA) coverage, Algeria, Iran and Egypt join Saudi and the UAE to form the most influential and attractive pharmaceutical...
2010-02-05Industry / United Arab Emirates
UAE generic drugmaker Julphar has revealed that its 2009 sales reached US$207mn, 21.9% higher than in 2008. The firm is confident it can continue on this upward trajectory and is...
2010-02-04Industry / South Africa
South African generic drugmaker Aspen Pharmacare has signed an agreement worth US$1mn with Eli Lilly to manufacture tuberculosis (TB) medicines, including one type specifically for...
2010-02-04Industry / United Kingdom
Multinational drugmaker GlaxoSmithKline (GSK) has posted full-year 2009 sales growth of 16%, increasing to GBP28.37bn (US$44.51bn) from GBP24.35bn (US$38.21bn) recorded in 2008. BMI notes that a more modest growth of 3% is calculated at constant exchange rates (CER), highlighting GSK's gain from the weaker pound sterling. The drugmaker earned profits after tax of GBP5.67bn (US$8.89bn),...
2010-02-05Industry
The European Generic Medicines Association (EGA)'s Vision 2015 calls for changes in the regulatory framework for generic and biosimilar medicines in order to create a globally competitive...
2010-02-05Industry / Ireland
In a move to cut spending, the Irish government has come to an agreement with the Irish Pharmaceutical Healthcare Association (IPHA) to cut the prices of approximately 300 prescription...
2010-02-04
